LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Allogene Therapeutics Inc

Closed

SectorHealthcare

1.17 -1.68

Overview

Share price change

24h

Current

Min

1.17

Max

1.22

Key metrics

By Trading Economics

Income

206K

-60M

EPS

-0.28

Profit margin

272,450

Employees

226

EBITDA

-302K

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+631.67% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

11M

267M

Previous open

2.85

Previous close

1.17

News Sentiment

By Acuity

100%

0%

364 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 cze 2025, 20:51 UTC

Earnings

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 cze 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 cze 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 cze 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 cze 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 cze 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 cze 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 cze 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 cze 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 cze 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 cze 2025, 18:39 UTC

Market Talk
Earnings

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 cze 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 cze 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 cze 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 cze 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 cze 2025, 17:08 UTC

Earnings

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 cze 2025, 16:52 UTC

Acquisitions, Mergers, Takeovers

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 cze 2025, 16:22 UTC

Earnings

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 cze 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 cze 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 cze 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 cze 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 cze 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

631.67% upside

12 Months Forecast

Average 8.78 USD  631.67%

High 14 USD

Low 4 USD

Based on 13 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

1.18 / 1.69Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

364 / 380 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.